Evotec SE (ETR:EVT)
Germany · Delayed Price · Currency is EUR | Market Cap | 504.81M -58.3% |
| Revenue (ttm) | 717.28M -7.7% |
| Net Income | -197.05M |
| EPS | -1.11 |
| Shares Out | 177.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 698,567 |
| Open | 2.918 |
| Previous Close | 2.858 |
| Day's Range | 2.798 - 2.920 |
| 52-Week Range | 2.406 - 7.300 |
| Beta | 1.27 |
| Analysts | Hold |
| Price Target | 4.44 (+56.34%) |
| Earnings Date | Nov 5, 2026 |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and c... [Read more]
Full Company ProfileFinancial Performance
In 2025, Evotec SE's revenue was 788.37 million, a decrease of -1.08% compared to the previous year's 796.97 million. Losses were -103.52 million, -47.21% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for EVT stock is "Hold." The 12-month stock price target is €4.44, which is an increase of 56.34% from the latest price.
News
Mubadala Investment Co PJSC Exits Evotec SE (EVOTF) -- Shares Look 57% Undervalued on GF Value
Mubadala Investment Co PJSC Exits Evotec SE (EVOTF) -- Shares Look 57% Undervalued on GF Value
Evotec appoints Joanna Holbrook as chief scientific officer
Evotec (EVO) announced the appointment of Joanna Holbrook as chief scientific officer and member of the management board, effective November 1. Holbrook brings to Evotec more than 25 years of…
Evotec Appoints Former Novo Nordisk Executive Joanna Holbrook As Chief Scientific Officer; Stock Up
(RTTNews) - Evotec SE (EVO, EVTG.DE, EVTCY.PK), a life science company, announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and member of the management board, effective Novem...
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board
Will lead Evotec's global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovation Brings more than 25 years of glob...
Evotec Sees 9-Month Results Above Market; Reiterates FY26 Outlook
(RTTNews) - Evotec SE (EVTG.DE, EVTCY.PK, EVO), a German healthcare company, announced preliminary results for the first nine months of 2026 that came in above market expectations, while reaffirming i...
Evotec's Preliminary 9-Month Results Beat Expectations; 2026 Guidance Holds
Evotec’s preliminary nine-month results beat market expectations, with revenue near €465 million and adjusted EBITDA of –€42.8 million, while its 2026 outlook remains unchanged.
EQS-Adhoc: Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance
EQS-Ad-hoc: Evotec SE / Key word(s): Forecast / Other Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance 13-Oct-2026 / 22:37 C...
Evotec Announces Chief Scientific Officer Transition
Dr. Cord Dohrmann to step down as of September 30, 2026 Search ongoing for a successor HAMBURG, Germany, Sept. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today an...
Evotec SE Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Scientific expertise and broad offerings differentiate the business, but clearer market messaging is needed. The Horizon program targets €75 million in savings and operational simplification, while new licensing and strategic deals are expected to drive margin growth. Key milestones include delivering on Horizon and clarifying segment dynamics.
EQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Total Voting Rights Announcement: Evotec SE / Total Voting Rights Announcement Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Euro...
Evotec initiates clinical trial evaluating JST-018
Evotec (EVO) announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its biologics CDMO sub...
Evotec Biologics Begins Phase 1 Trial For Orthopoxvirus Antibody Program
(RTTNews) - Evotec SE (EVO) has announced the start of a first-in-human Phase 1 trial for JST-018, a cocktail of investigational monoclonal antibodies designed to target orthopoxviruses.
Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies Program Supports development of countermea...
Evotec, Plectonic Biotech announce immunotherapy research collaboration
Evotec (EVO) and Plectonic Biotech announced a research collaboration to explore an immunotherapy approach for solid tumors. The collaboration addresses key challenges that have so far limited the suc...
Evotec, Plectonic Enter Research Collaboration For T-Cell-Engaging Solid Tumour Therapies
(RTTNews) - Evotec SE (EVO), a life sciences company, and Plectonic Biotech announced a research collaboration to explore a novel immunotherapy approach for solid tumours. The collaboration aims to ad...
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
Collaboration aims to validate Evotec's proprietary BiTco costimulatory CD2 bispecifics platform in combination with Plectonic's logic-gated DNA-protein immunotherapy technology LOGIBODY® BiTco design...
Evotec SE Quarterly report: Q2 2026
Evotec SE has published its Q2 2026 quarterly earnings report on August 13, 2026.
Evotec enters R&D collaboration with Odyssey Therapeutics
Evotec (EVO) announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics (ODTX) to discover potential new treatments in autoimmune and inflammatory diseases. Under the agreem...
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Ody...
Niagen Bioscience selects Evotec to advance development for NB4168
Niagen Bioscience (NAGE) announced that it has selected Evotec (EVO) as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD…
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Evotec SE Slides: Company presentation
Evotec SE has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management
PALO ALTO, Calif.--(BUSINESS WIRE)--Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the glob...
Evotec price target lowered to EUR 3.50 from EUR 4.50 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Evotec (EVO) to EUR 3.50 from EUR 4.50 and keeps a Hold rating on the shares.
Evotec downgraded to Hold from Buy at Berenberg
Berenberg downgraded Evotec (EVO) to Hold from Buy with a price target of EUR 3.60, down from EUR 9.40. The company reported “disappointing” first half of 2026 results and significantly…